SPECT in early- and late-onset Alzheimer's disease

Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy

We have studied whether it is possible to discriminate responders to tacrine treatment from patients nonresponsive to tacrine in Alzheimer's disease. The results indicate that mildly demented patients will most likely gain a benefit of tacrine treatment. Neuropsychological tests on attention and working memory after a single dose of tacrine might be useful as well as a single dose pharmaco-EEG in discriminating responders to treatment.

SPECT measurements of brain function in dementia; a review

A brief review of the role of SPECT (single photon emission computed tomography) in the diagnosis of dementing brain disease is given. Between 1990 and 1995 some 100 original articles deal with SPECT measurements with radioactive tracers of brain function in demented patients. The main field is measurement of regional cerebral blood flow (rCBF) but there is an increasing number of studies concerning receptor functions in the demented brain.

Canadian guidelines for the development of antidementia therapies: a conceptual summary

The magnitude of the problems faced by Canadian society as a result of an aging population has been identified. Perhaps the most important concern related to this greying of Canada is the increasing incidence of dementia and Alzheimer's disease. Therapeutic options for these disorders have been limited to date. Advances in biotechnology and molecular biology will offer novel approaches to treatment. These and the expansion of more traditional therapeutic avenues require guidelines with the aim of optimizing their development.